What the company or idea is
Eisai is a Japanese pharmaceutical company founded in 1941, headquartered in Tokyo, formed via merger in 1944, with a documented history of internal drug discovery and strategic oncology acquisitions between 2006 and 2007.
How it actually makes money
Eisai makes money by discovering drugs in-house (e.g., Aricept), co-marketing them with global partners (Pfizer, Johnson & Johnson), and acquiring oncology assets — including four products from Ligand Pharmaceuticals in 2006 and two companies (Morphotek and MGI Pharma) in 2007, the latter for US$3.9 billion.
What works
Co-marketing works: Aricept (1996) and Aciphex (1999) gained USFDA approval and global reach via Pfizer and Johnson & Johnson. Oncology acquisition also worked as a growth lever — four products in 2006, then two companies in 2007.
What does not
The sources do not establish any revenue, profit margin, R&D spend, market share, or therapeutic success rate. They show no evidence of Eisai’s internal discovery pipeline beyond Aricept, nor any post-2007 strategy beyond oncology consolidation.
What to take from it
Eisai’s model reveals a deliberate pivot: from Japan-centric R&D and co-marketing partnerships to US-focused oncology control — paid for with a $3.9 billion acquisition — without evidence of integrated commercial capability beyond those deals.
Is it worth your time
Yes — if you are studying how mid-tier pharma firms scale through targeted acquisition rather than organic globalisation, or how co-marketing offsets late-stage commercialisation risk.
